Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0UKVRD
ADC Name	WO2017089890A1 ADC65
Synonyms	Cetuximab_compound 25e (DAR 4) Click to Show/Hide
Organization	LegoChem Biosciences, Inc.
Drug Status	Investigative
Indication	In total 2 Indication(s) Lung cancer [ICD11:2C25] Investigative Skin squamous cell carcinoma [ICD11:2C31] Investigative
Drug-to-Antibody Ratio	4
	3D MOL	2D MOL
Antibody Name	Cetuximab		Antibody Info
Antigen Name	Epidermal growth factor receptor (EGFR)		Antigen Info
Payload Name	Monomethyl auristatin E		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	WO2017089890A1_ADC65 linker
Conjugate Type	Site-specific conjugation through nucleophilic lysines.

General Information of The Activity Data Related to This ADC

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Inhibitory Concentration (IC50)	0.17	nM	CVCL_2063	Lung adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	> 33.3	nM	CVCL_0031	Invasive breast carcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.17 nM	Moderate EGFR expression (EGFR++)
Method Description	The cells were incubated at 37°C in 5% CO, for 24 hours. Then, serial dilutions of monomethyl auristatin F ADCs were added to the cells at concentrations of 100 to 0.00128 nM. The cells were incubated for 72 hours and then fixed for 1 hour at 4after adding 100 L ofice-cold 10% trichloroacetic acid to each well.
In Vitro Model	Lung adenocarcinoma	HCC827 cells		CVCL_2063
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 33.30 nM	Negative EGFR expression (EGFR-)
Method Description	The cells were incubated at 37°C in 5% CO, for 24 hours. Then, serial dilutions of monomethyl auristatin F ADCs were added to the cells at concentrations of 100 to 0.00128 nM. The cells were incubated for 72 hours and then fixed for 1 hour at 4after adding 100 L ofice-cold 10% trichloroacetic acid to each well.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

References

Ref 1	Conjugates comprising self-immolative groups and methods related thereto.